Abstract
A 73-year-old man with primary myelofibrosis (PMF) was being treated with hydroxyurea, which was changed to ruxolitinib treatment because of worsening constitutional symptoms. Although ruxolitinib rapidly induced relief, he developed a high-grade fever. A comprehensive fever work-up found no apparent cause of the fever, except for PMF. Therefore, we increased the dose of ruxolitinib and added prednisolone, which was gradually withdrawn with resolution of the fever. However, the patient subsequently developed disseminated tuberculosis and died eight months after initiation of ruxolitinib. Our case highlights the importance of assessing and monitoring the immune status of patients receiving ruxolitinib.
| Original language | English |
|---|---|
| Pages (from-to) | 1297-1300 |
| Number of pages | 4 |
| Journal | Internal Medicine |
| Volume | 57 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Jan 1 2018 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Internal Medicine
Cite this
Fatal disseminated tuberculosis during treatment with ruxolitinib plus prednisolone in a patient with primary myelofibrosis : A case report and review of the literature. / Tsukamoto, Yasuhiro; Kiyasu, Junichi; Tsuda, Mariko; Ikeda, Motohiko; Shiratsuchi, Motoaki; Ogawa, Yoshihiro; Yufu, Yuji.
In: Internal Medicine, Vol. 57, No. 9, 01.01.2018, p. 1297-1300.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Fatal disseminated tuberculosis during treatment with ruxolitinib plus prednisolone in a patient with primary myelofibrosis
T2 - A case report and review of the literature
AU - Tsukamoto, Yasuhiro
AU - Kiyasu, Junichi
AU - Tsuda, Mariko
AU - Ikeda, Motohiko
AU - Shiratsuchi, Motoaki
AU - Ogawa, Yoshihiro
AU - Yufu, Yuji
PY - 2018/1/1
Y1 - 2018/1/1
N2 - A 73-year-old man with primary myelofibrosis (PMF) was being treated with hydroxyurea, which was changed to ruxolitinib treatment because of worsening constitutional symptoms. Although ruxolitinib rapidly induced relief, he developed a high-grade fever. A comprehensive fever work-up found no apparent cause of the fever, except for PMF. Therefore, we increased the dose of ruxolitinib and added prednisolone, which was gradually withdrawn with resolution of the fever. However, the patient subsequently developed disseminated tuberculosis and died eight months after initiation of ruxolitinib. Our case highlights the importance of assessing and monitoring the immune status of patients receiving ruxolitinib.
AB - A 73-year-old man with primary myelofibrosis (PMF) was being treated with hydroxyurea, which was changed to ruxolitinib treatment because of worsening constitutional symptoms. Although ruxolitinib rapidly induced relief, he developed a high-grade fever. A comprehensive fever work-up found no apparent cause of the fever, except for PMF. Therefore, we increased the dose of ruxolitinib and added prednisolone, which was gradually withdrawn with resolution of the fever. However, the patient subsequently developed disseminated tuberculosis and died eight months after initiation of ruxolitinib. Our case highlights the importance of assessing and monitoring the immune status of patients receiving ruxolitinib.
UR - http://www.scopus.com/inward/record.url?scp=85046290264&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046290264&partnerID=8YFLogxK
U2 - 10.2169/internalmedicine.9165-17
DO - 10.2169/internalmedicine.9165-17
M3 - Article
C2 - 29279479
AN - SCOPUS:85046290264
VL - 57
SP - 1297
EP - 1300
JO - Internal Medicine
JF - Internal Medicine
SN - 0918-2918
IS - 9
ER -